| Cat. No. |
Product Name |
CAS No. |
Information |
| H9466 |
Farudodstat
|
1035688-66-4 |
ASLAN003 (LAS 186323) is a potent and orally active inhibitor of DHODH (Dihydroorotate dehydrogenase) with IC50 of 35 nM for human DHODH enzyme activity; ASLAN003 impairs protein synthesis and induces the differentiation and apoptosis transcriptional program in acute myeloid leukemia (AML) cells via activation of AP-1 transcription factors. |
| H9331 |
Ibrigampar
|
315224-26-1 |
Ibrigampar is a highly potent, non-TZD, selective peroxisome proliferator-activated receptor gamma (“PPAR-γ“) modulator (SPPARM); INT131 is a PPAR-γ partial agonist and potential therapeutic agent for the treatment of type 2 diabetes. |
| H9308 |
RO0711401
|
714971-87-6 |
RO0711401 is a selective and orally active positive allosteric modulator of mGlu1 receptor with an EC50 of 56 nM. |
| H8972 |
Tolebrutinib
|
1971920-73-6 |
Tolebrutinib is an oral, brain-penetrant, selective small molecule inhibitor of Bruton's tyrosine kinase (BTK). |
| H6471 |
Laquinimod
|
248281-84-7 |
Laquinimod (ABR-215062) is an immunoregulator derived from Linomide, has been shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (EAE); dose-dependently reduces the incidence of EAN, ameliorated clinical signs and inhibited P0 peptide 180-199-specific T cell responses as well as also the decreased inflammation and demyelination in the peripheral nerves; shows improved potency and superior toxicological profile compared to the lead compound Roquinimex (Linomide). |
| H6170 |
AZD5904
|
618913-30-7 |
AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat; displays 10 to 19-fold selective compared to the closely related lactoperoxidase and thyroid peroxidase, >70-fold to a broad panel of other enzymes, ion channels, and receptors; 1 ¦ÌM AZD5904 inhibited PMA stimulated HOCl by >90% in isolated human neutrophils; a plasma concentration of ~5 ¦ÌM decreased the in vivo formation of glutathione sulphonamide in rats. |
| H5839 |
Dimethyl fumarate
|
624-49-7 |
Dimethyl fumarate (DMF;BG-12) exerts anti-inflammatory and pro-metabolic effects in a variety of cell types; an effective novel treatment for multiple sclerosis; activates the Nrf2 pathway and has been identified as a nicotinic acid receptor agonist in vitro. |
| H5492 |
Guanabenz
|
5051-62-7 |
Guanabenz (WY 8678) is an α2 adrenergic receptor agonist that is used as an antihypertensive agent, also has been proposed to exert protective effects against misfolding by interfering with eIF2α-P dephosphorylation through selective disruption of a PP1-PPP1R15A holophosphatase complex; also has antiparasitic activity against replicative stages of Toxoplasma. |
| H4071 |
Fingolimod hydrochloride
|
162359-56-0 |
Fingolimod (FTY 720) is an immunomodulatory agent can be phosphorylated by SphK, then functions as a potent agonist of S1P receptors (S1P1/3/4/5) with EC50 of 0.3-5 nM; has no affitnity for S1P2; alters lymphocyte trafficking and inhibits lymphocyte recirculation. |
| H3482 |
Siponimod
|
1230487-00-9 |
Siponimod (BAF312) is a potent, selective S1P1/S1P5 receptor modulator with EC50 of 0.39/0.0.98 nM, >1,000-fold selectivity over S1P2/3/4; suppresses ongoing disease symptoms in rat EAE, concentration-dependently increases GIRK current amplitude in atrial myocytes with EC50 of 15.8 nM, reduces peripheral absolute lymphocyte counts in vivo, exhibits potential as a treatment for immune-mediated diseases. |
$ USD
Select Your Country or Region
